Newleos Therapeutics has officially launched with an oversubscribed Series A financing round, raising $93.5 million to develop innovative treatments for neuropsychiatric disorders. The funding was supported by notable investors, including Andreessen Horowitz, Lux Capital, and Point72 Ventures. The company aims to advance a portfolio of experimental central nervous system (CNS) drugs that originated from Roche. This initiative highlights a growing interest in the neuropsychiatry sector, as venture capital continues to flow into startups focusing on mental health and related therapies.